FDA approves Akeega for BRCA-positive metastatic prostate cancer

Health News
Tags :
Health News
Share This :

FDA approves akeega for BRCA-positive metastatic prostate cancer

The U.S. Food & Drug Administration has approved Akeega (niraparib and abiraterone acetate) for the treatment of BRCA-positive metastatic castration-resistant prostate cancer.

The approval makes Akeega the first and only dual action tablet combining a poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitor with abiraterone acetate, given with prednisone.

The FDA approval is based on positive results from the randomized multicenter phase 3 MAGNITUDE study. Patients treated with the combination of Akeega plus prednisone had a statistically significant risk reduction in radiographic progression-free survival (rPFS). At a median follow-up of 24.8 months at the second interim analysis, rPFS, as adjudicated by central review, demonstrated a consistent trend favoring Akeega plus prednisone, with a median rPFS of 19.5 months versus 10.9 months for placebo and abiraterone acetate plus prednisone (AAP).

There was also improvement seen in the secondary end points of time to symptomatic progression and time to initiation of cytotoxic chemotherapy for Akeega plus prednisone versus AAP alone. There was also a trend observed toward improvement in overall survival.

“As a physician, identifying patients with a worse prognosis is a priority, especially those whose cancers have a BRCA mutation,” Kim Chi, M.D., the principal investigator of the phase 3 MAGNITUDE study, said in a statement. “We prospectively designed the MAGNITUDE study to identify the subset of patients most likely to benefit from targeted treatment with Akeega and to help us understand how we can potentially achieve better health outcomes for patients.”

Approval of Akeega was granted to Janssen.

More information:
www.janssen.com/fda-approves-a … y-dual-action-tablet

Copyright © 2023 HealthDay. All rights reserved.

FDA approves Akeega for BRCA-positive metastatic prostate cancer (2023, August 18)
retrieved 19 August 2023
from https://medicalxpress.com/news/2023-08-fda-akeega-brca-positive-metastatic-prostate.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *

Popular News Posts


Our Exclusive Products

Our Store

Our mission is simple, offer quality products that make our customers lives better at a reasonable price, while ensuring a hassle-free shopping experience. This means that before we bring a product to market, we test it to ensure that it meets our high-level quality standards. Our customer service team understand our products and can answer most every product related question quickly and efficiently. We strive everyday to meet and exceed our customers’ expectations of quality and support! Should we ever fail to meet this expectation – contact us and we will make it right!

Our Value: We are proud of our product and accomplishments, but we typically don’t shout it from the rooftop. Instead, we prefer to let our product and customers do the talking. Our core values can be recognized in our product. The qualities we strive for include:

Pragmatism: We design simple, useful solutions for common needs
Quality: From design to final product, we strive for durable solutions that work
Originality: Creativity and innovation are what makes our product unique
Design: Our minimalist and bold design language focuses on functionality and simplicity that is timeless

0 +

Top Rated Products

0 +

Happy Customers